Accession Number:

AD1190634

Title:

Detection and Treatment of Ovarian Cancer by Targeting Tumor Extracellular Hydroxyapatite: A New Paradigm

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

VANDERBILT UNIV MEDICAL CENTER NASHVILLE TN

Personal Author(s):

• Tantawy, Mohammed
• McIntyre, J

Report Date:

2022-05-01

Pagination or Media Count:

21

Abstract:

In this report, we continue to evaluate tumor extracellular hydroxyapatite HAP, Ca10PO46OH2, asan imaging biomarker of ovarian cancer a target for therapy. We have shown that HAP-binding radiotracers such asFDA-approved 18F-NaF can be used with PET imaging and 99mTc-MDP with SPECT imaging to detect breasttumors in this context, detection of tumor-associated HAP exhibited high specificity and a high signal-tobackground ratio SBR as HAP is absent in normal soft tissue. In ovarian cancer, conventional imaging modalitieslack clear metrics for assessing tumor burden before and after surgical debulking and for assessing tumor responseto therapy. This is mainly due to lack of specificity andor low SBR ratio from standard imaging. Additionally, wehad developed a nanoparticulate sulfonated polystyrene solution NSPS to break-up HAP in vivo inducing alocalized alkalosis status in the tumor microenvironment inhibiting tumor growth.

Descriptors:

• medical personnel
• breast cancer
• abdomen
• neoplasms
• oncology
• cancer
• detection
• soft tissues
• standards
• fungi
• metabolism
• spectroscopy
• biomedical research
• cell line
• cells
• mammary glands
• ovarian cancer

Subject Categories:

Distribution Statement:

[A, Approved For Public Release]